Andreas comments below out of the Annual Report
It is difficult to overstate just how excited we are by the clinical data our trials have unlocked over the past year. As an example, in May 2022, investigators from Johns Hopkins and University of Miami presented findings from their COPD study. Results demonstrated that XV Technology® shows significant promise as a tool to phenotype or classify COPD disease, which is critical to optimising treatment therapies. More recently, 4DMedical announced a major success in the Vanderbilt ‘burn pit’ clinical trial. This trial was designed to test the capability of XV Technology® to determine the presence of respiratory disease in Veterans exposed to airborne hazards while on deployment.
Andreas comments below out of the Annual Report It is difficult...
-
- There are more pages in this discussion • 1,643 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.005(0.94%) |
Mkt cap ! $215.4M | |||
| Open | High | Low | Value | Volume |
| 52.5¢ | 53.0¢ | 51.5¢ | $146.0K | 279.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21156 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 310 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |